Compare RNTX & QXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RNTX | QXL |
|---|---|---|
| Founded | 2001 | N/A |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.3M | 75.6M |
| IPO Year | 2017 | 2015 |
| Metric | RNTX | QXL |
|---|---|---|
| Price | $0.78 | $4.70 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 427.7K | 56.9K |
| Earning Date | 05-15-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.16 | N/A |
| EPS | N/A | ★ 0.10 |
| Revenue | N/A | ★ $26,941,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $47.10 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.69 | $4.05 |
| 52 Week High | $2.18 | $7.70 |
| Indicator | RNTX | QXL |
|---|---|---|
| Relative Strength Index (RSI) | 44.63 | 47.64 |
| Support Level | $0.69 | $4.12 |
| Resistance Level | $0.88 | $5.04 |
| Average True Range (ATR) | 0.06 | 0.35 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 19.75 | 65.91 |
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
Quantum X Labs Inc is an Israel-based multi-disciplinary quantum technology company focused on the research, development, and commercialization of quantum technologies and intellectual property. The company operates across a broad range of domains, including quantum computing, quantum sensing, navigation systems, atomic clocks, and quantum algorithms, with applications spanning defense, aerospace, transportation, cybersecurity, and life sciences.